Pill vs. needle: can Lower-Dose blood thinners protect blood cancer patients from deadly clots?

NCT ID NCT07270263

Recruiting now Disease control Sponsor: Medical University of Gdansk Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two types of blood thinners taken as pills (apixaban and rivaroxaban) against a standard daily injection (enoxaparin) to prevent dangerous blood clots in people with blood cancers like lymphoma, leukemia, and multiple myeloma. About 100 participants will be randomly assigned to one of the three treatments for at least six months. The goal is to see which option is safest and most effective at preventing clots while minimizing bleeding risks.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: apixaban, rivaroxaban, and enoxaparin (low-molecular-weight heparin)
What this could lead to: If successful, this could offer blood cancer patients a safer, more convenient pill option to prevent blood clots, reducing the need for daily injections.
What could go wrong: This is a small, early-phase study with only 100 participants, so results may not apply to all patients. There is a risk of bleeding with any blood thinner.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEMATOLOGIC MALIGNACIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid cell neoplasm hematopoietic and lymphoid system neoplasm leukemia lymphoma myeloproliferative neoplasm plasma cell myeloma pulmonary embolism venous thromboembolism

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEMATOLOGIC MALIGNACIES LEUKEMIA LYMPHOMA MULTIPLE MYELOMA (MM), LYMPHOMA, LARGE B-CELL, DIFFUSE (DLBCL), LYMPHOMA PE - PULMONARY EMBOLISM VENOUS THROMBOEMBOLIC DISEASE VTE (VENOUS THROMBOEMBOLISM)

Contacts and locations

Locations

Department of Haematology & Transplantology
RECRUITING

Gdansk, Pomeranian Voivodeship, 80-152, Poland

More trials for these conditions

Other studies related to the condition(s) this trial covers.